Beezaasan Explotech Ltd will hold an Extra-Ordinary General Meeting on October 13, 2026, to seek shareholder approval for raising Rs 29.28 crore through a preferential issue. The company plans to increase its authorised share capital to Rs 46 crore to accommodate the move. Key investors, including Ashish Kacholia, are set to be allotted shares at Rs 570 apiece. The funds are earmarked for working capital, capital expenditure, and operational requirements.
Beezaasan Explotech Sets EGM to Approve Rs 29 Crore Capital Infusion
Beezaasan Explotech Ltd has announced an Extra-Ordinary General Meeting (EGM) scheduled for October 13, 2026, to finalize a major capital restructuring plan. The firm intends to raise Rs 29.28 crore via a preferential issue of 5,13,772 equity shares priced at Rs 570 each.
Reader Takeaway: The infusion of Rs 29 crore strengthens liquidity; however, the preferential issue dilutes current shareholding percentages.
What just happened
The company has formally notified shareholders of an EGM to be held via video conferencing. The primary agenda involves increasing the authorised share capital from Rs 16 crore to Rs 46 crore and approving the issuance of equity shares to a specific group of investors. Notable participants in this round include Ashish Kacholia, who is slated to receive 3,42,637 shares, and Kadayam Ramanathan Bharat, among others.
Why this matters
This capital injection provides the necessary financial buffer for Beezaasan Explotech to scale its operations. The proceeds are designated for long-term working capital, procurement of raw materials, and funding capital expenditure. By securing funds from high-profile investors, the company signals a push to bolster its balance sheet and support upcoming business growth targets over the next year.
What changes now
Upon shareholder approval at the upcoming EGM, the company will proceed with the allotment of shares. These new shares will be listed on the BSE and will carry standard lock-in provisions as mandated by SEBI ICDR regulations. The increase in authorised share capital ensures the company has enough headroom for future equity issuances if required.
What to track next
Investors should closely monitor the outcome of the EGM vote and the official allotment timeline. Additionally, tracking how effectively the company deploys these funds toward working capital and inventory management over the next 12 months will be critical for long-term value creation.